The largest database of trusted experimental protocols

Genexpert system

Manufactured by Cepheid
Sourced in United States, France

The GeneXpert system is a molecular diagnostic platform developed by Cepheid. It is designed to perform automated, real-time PCR (polymerase chain reaction) analysis of samples to detect the presence of specific genetic sequences. The system integrates sample preparation, nucleic acid extraction, amplification, and detection into a single, self-contained unit. The GeneXpert system is capable of processing multiple sample types, including blood, respiratory, and other clinical specimens.

Automatically generated - may contain errors

63 protocols using genexpert system

1

SARS-CoV-2 Detection via BioFire and GeneXpert

Check if the same lab product or an alternative is used in the 5 most similar protocols
After induction of anesthesia and orotracheal intubation, a nasopharyngeal swab was collected and placed into 3 mL of M4‐RT viral transport media (Remel, US). The FDA‐approved BioFire® FilmArray® Respiratory 2 (RP2) Panel was performed according to the manufacturer's instructions.10 In brief, this closed test system performs sample preparation, reverse transcription, polymerase chain reaction, and detection of 21 respiratory pathogens using 300 μL of inoculated M4‐RT viral transport media. SARS‐CoV‐2 analysis was performed on the GeneXpert System using the emergency use authorization (EUA)‐approved Xpert Xpress SARS‐CoV‐2 test (Cepheid, Sunnyvale, CA) according to the manufacturer's instructions.11 In brief, a defined volume of sample (nasopharyngeal swab specimen in 3‐mL M4‐RT) is transferred to the testing cartridge and placed on the GeneXpert System, which integrates sample preparation, nucleic acid extraction, and real‐time PCR‐based amplification and detection of target sequences (N2 and E genes). The limit of detection of this test is 250 copies/mL. SARS‐CoV‐19 analysis was only conducted on patient samples from January 2020 to March 2020 (n = 75) due to availability of previously stored samples.
+ Open protocol
+ Expand
2

Evolution of C. difficile Detection Algorithms

Check if the same lab product or an alternative is used in the 5 most similar protocols
During the study period, C difficile testing was performed only on unformed stool samples on specific request by physicians. Before November 2011, the presence of C difficile was assessed by enzyme immunoassay (EIA; ImmunoCard Toxins A&B, Meridian Biosciences) of fresh stool samples coupled with culture (algorithm, Alg1). For culture, stool samples were plated on CLO medium (Biomérieux) and incubated in anaerobic conditions at 37°C for 48 hours. If the assay yielded negative toxin results and the culture was positive for C difficile, isolate toxicity was assessed in vitro (toxigenic culture). Between November 2011 and January 2013, an algorithm protocol was used involving glutamate dehydrogenase (GDH) (ImmunoCard C difficile GDH assay; Meridian Biosciences) antigen screening test, and if it was positive, stools were subsequently tested for C difficile toxins A and B by EIA and culture as previously described (Alg2). Beginning in February 2013, the laboratory replaced the last algorithm with a combined immunochromatographic test of GDH and toxins (C. DIFF QUIK CHEK COMPLETE; Alere) coupled with polymerase chain reaction (PCR) (GeneXpert Systems, Cepheid). If the screening test was positive and the toxins were negative, PCR was then performed as a confirmatory test (Alg3).
+ Open protocol
+ Expand
3

Cost-Effective Mobile Xpert MTB/RIF Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols
As a comparator, the cost per result was determined for traditional laboratory-based Xpert MTB/RIF testing. Initial laboratory setup included the installation of the four GeneXpert systems (Cepheid, Sunnyvale, California, United States) (capacity of 64 samples per day), an air conditioner, a level two biosafety hood and a vortex mixer. Operational costs included costs to procure reagents, consumables, specimen collection materials, quality control materials (internal and external), printer cartridges and paper. The assumptions for these operational costs were similar to those for mobile testing.
The staff complement required to perform mobile testing included a medical technologist and a laboratory manager, who provided minimal supervision. The technologists performed other testing in addition to Xpert MTB/RIF. The costs of the business management unit (coordinator costs) in the North West province were determined and included the following personnel: business manager, secretary, quality assurance coordinator, human resources officers, training staff, and other support staff. To determine the coordinator costs per result, the AEC was divided by the annual test volume for the province. For the courier costs, the annual expenditure for the laboratory was used.
+ Open protocol
+ Expand
4

Rapid C. difficile Identification Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patients diagnosed with C. difficile infection at the Baruch Padeh Medical Center, Poriya in northern Israel, were enrolled in the study from January 2015 to May 2017. The identification of CDI was performed by stool examination for toxigenic C. difficile at the Clinical Microbiology Laboratory by Xpert®C. difficile Assay (Cepheid, Solna, Sweden), performed on Cepheid GeneXpert® Systems. This is a qualitative in vitro real-time PCR for the rapid identification of C. difficile. The study was approved by the Poriya Baruch Padeh Medical Center Helsinki Committee without the need for patients to sign an informed consent form because the study deals with microbial isolates and the results of the study do not affect the patients.
+ Open protocol
+ Expand
5

Diagnosis of Clostridioides difficile Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Diagnosis of CDI was based on current recommendations, using a two-step algorithm with a combined test of GDH and toxins (C. DIFF QUIK CHEK COMPLETE®, Alere, Waltham, MA, USA) followed by PCR (GeneXpert® Systems, Cepheid, Sunnyvale, CA, USA) in cases of non-contributing result.
For a GDH-positive sample, quantitative culture was performed. At least 3 colonies by culture were characterized at the National Reference Center (NRC) by PCR multiplex detection of tcdA, tcdB, tpi, tcdC, cdtA, cdtB genes and PCR ribotyping [24 (link),25 (link)].
+ Open protocol
+ Expand
6

COVID-19 Molecular Diagnostic Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols
As part of the outbreak response, samples were collected from nasopharyngeal SARS-CoV-2 swabs and were sent to the laboratories of the RI Department of Health. The standard technique used to identify SARS-CoV-2 was real-time reverse-transcriptase polymerase chain reaction (RT-PCR). The molecular assays used were GeneXpert® Systems (Cepheid, Sunnyvale, CA, USA) and Aptima® Systems (Hologic Inc., San Diego, CA, USA). The turnaround time for the COVID-19 molecular diagnostic testing was 48 h.
+ Open protocol
+ Expand
7

Carbapenem-Resistant Klebsiella pneumoniae Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
We identified the 5 K. pneumoniae strains by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonik GmbH, https://www.bruker.com). We identified carbapenemase genes by PCR using the GeneXpert system (Cepheid, https://www.cepheid.com) and used the lateral flow immunochromatography systems (NG-Test CARBA 5; Hardy Diagnostics, https://www.hardydiagnostics.com). We tested antimicrobial drug susceptibility by using the MicroScan WalkAway system (Beckman Coulter, Inc., https://beckman.com). We used gradient strips (Liofilchem, https://www.liofilchem.com) to test MVB and CZA MICs and the Compact Antimicrobial Susceptibility Panel (ComASP; Liofilchem) to test FDC MICs.
+ Open protocol
+ Expand
8

Integrated Antenatal STI Screening and Treatment in Botswana

Check if the same lab product or an alternative is used in the 5 most similar protocols
Our study took place in an antenatal clinic in Gaborone, Botswana. In Botswana, antenatal care attendance is high, more than 92% of antenatal care attendees are tested for HIV through a routine, opt-out system, and 33% of pregnant women are infected with HIV [18 ]. The standard care for curable infections such as CT, NG, and TV, includes identifying and treating infections based on symptoms and clinical signs, called syndromic management. Partner notification is patient-based, and women believed to have an STI are encouraged by health providers to inform their sex partner(s), and are provided with a contact slip to give to partner(s) that details the symptom being treated (e.g. abnormal vaginal discharge), the treatment (e.g. azithromycin), and the date and location of treatment [19 ]. This study was nested within a CT, NG, and TV infection testing and treatment intervention (main study) that was integrated into an antenatal care clinic using the GeneXpert® System (Cepheid, Sunnyvale, CA, USA). The main study offered the standard care for partner services but differed from syndromic management of STIs by making an etiologic diagnosis of STIs and treating based on this diagnosis (not signs and symptoms).
+ Open protocol
+ Expand
9

Vancomycin-resistant Enterococcus faecium Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
Due to previous episodes of transmission of vancomycin-resistant E. faecium in a department of haematology, the detection of E. faecium carrying the vanA gene in the urine of patients in this department was followed up by screening of all patients in the department using the GeneXpert system (Cepheid, CA, USA) [23 (link)].
+ Open protocol
+ Expand
10

Characterization of Carbapenem-Resistant K. pneumoniae

Check if the same lab product or an alternative is used in the 5 most similar protocols
The K. pneumoniae strain, namely SA-KpST14, was recovered from a 40-year-old female with rheumatic heart disease (RHD) at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. The initial antimicrobial susceptibility testing was performed using the VITEK‑2 system (BioMerieux, Brussels, Belgium). Etest (bioMérieux, Durham, NC) was used to determine the MICs for aztreonam, imipenem, ceftazidime/avibactam and synergetic activities of antibiotic combinations listed in Table 1. Antimicrobial MIC interpretations were in accordance to CLSI guidelines. A zone of hope for antimicrobial activity was defined based on the definition of synergy (1 plus 1 equals more than 2); hence, a zone of hope is defined as (0 plus 0 equals more than 1)50 (link). MICs of colistin were confirmed by broth dilution methods done according to CLSI guidelines. Carba-R test using GeneXpert system (Cepheid, USA) was initially used to detect the presence of carbapenemase-resistance genes.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!